Psoriasis is a chronic, immune‐mediated disease affecting more than 100 million people
worldwide and up to 2.2% of the UK population. The aetiology of psoriasis is thought to …

Psoriasis is a prevalent, chronic inflammatory disease of the skin, mediated by crosstalk
between epidermal keratinocytes, dermal vascular cells, and immunocytes such as antigen …

This evidence‐and consensus‐based guideline on the treatment of psoriasis vulgaris was
developed following the EuroGuiDerm Guideline and Consensus Statement Development …

Psoriasis is a chronic, inflammatory, multisystem disease that affects up to 3.2% of the
United States population. This guideline addresses important clinical questions that arise in …

Methotrexate (MTX) is one of the first-line treatments for moderate to severe psoriasis, while
the side effects caused by injection and oral administration of MTX greatly restrict its clinical …

Background Ixekizumab is a humanised monoclonal antibody against the proinflammatory
cytokine interleukin 17A. We report two studies of ixekizumab compared with placebo or …

Background Apremilast, an oral phosphodiesterase 4 inhibitor, regulates immune responses
associated with psoriasis. Objectives ESTEEM 2 evaluated the efficacy and safety of …

European evidence‐based (S3) guideline for the treatment of acne – update 2016 – short
version - Nast - 2016 - Journal of the European Academy of Dermatology and Venereology …

Generalized pustular psoriasis (GPP) is a rare disease characterized by recurrent fever and
systemic flushing accompanied by extensive sterile pustules. The committee of the …

Background New therapeutic options are needed for patients with psoriasis. Tofacitinib, an
oral Janus kinase inhibitor, is being investigated as a treatment for moderate-to-severe …